NCT03373305撤回1 期
A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas
City of Hope Medical Center1 个研究点 分布在 1 个国家开始时间: 2019年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Dose limiting toxicity (DLT) assessed per CTCAE v4.0
研究概览
简要总结
This phase I trial studies the side effects and best dose of lenalidomide when given together with brentuximab vedotin in treating patients with T-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphomas.
详细描述
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD)/Recommended Phase 2 dose (RP2D) of brentuximab vedotin in combination with lenalidomide in patients with relapsed/ refractory cutaneous T-cell lymphoma (CTCL).
II. Assess safety and tolerability of brentuximab vedotin in combination with lenalidomide in patients with relapsed/ refractory CTCL.
SECONDARY OBJECTIVES:
I. Estimate the rate of objective global response that lasts at least 4 months (ORR4) , complete response (CR) rate, progression-free survival (PFS) of brentuximab vedotin in combination with lenalidomide in patients with relapsed/ refractory CTCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented informed consent of the participant and/or legally authorized representative
- •Registered into mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
- •Women of childbearing potential: adhere to scheduled pregnancy testing as required in the Revlimid REMS program
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Histologically confirmed cutaneous T-cell non-Hodgkin lymphoma (CTCL) per World Health Organization (WHO) classification 2016 including, mycosis fungoides (MF) or Sezary syndrome (SS); phase 1 : >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; expansion cohort: >= stage IB
- •MF/SS stage of disease according to TNMB classification
- •SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria
- •For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society for Cutaneous Lymphomas (ISCL) should be used
- •Relapsed/refractory disease
- •Failed >= 2 prior systemic therapies
- •CD30-positivity by immunohistochemistry of >= 1%
- •Measurable disease per modified Severity Weighted Assessment and/or Sezary count
- •Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1
- •May have received either brentuximab vedotin or lenalidomide/immunomodulatory imide drugs (IMiD) without dose modification/delay due to toxicity
- •* IMiDs defined as thalidomide analogues
- •If received prior brentuximab vedotin or lenalidomide, must be able to tolerate the dose level to which the participant will be enrolled to
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Absolute neutrophil count (ANC) >= 1,000/mm^3
- •* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Platelets >= 75,000/mm^3
- •* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Total bilirubin =< 1.5 X upper limit of normal (ULN) OR if Gilbert's syndrome =< 3.0 X ULN
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Aspartate aminotransferase (AST) =< 2 x ULN
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Alanine aminotransferase (ALT) =< 2 x ULN
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula
- •Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
排除标准
- •Stem cell transplantation
- •Monoclonal antibody within 28 days prior to day 1 of protocol therapy
- •Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating day 1 of protocol therapy
- •Any skin-directed therapy within 14 days prior to day 1 of protocol therapy
- •Any radiation therapy within 21 days prior to day 1 of protocol therapy
- •Immunosuppressive medication within 14 days prior to day 1 of protocol therapy; the following are exceptions to this criterion:
- •Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days
- •Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalent
- •Live, attenuated vaccine within 30 days prior to day 1 of protocol therapy
- •Disease free of prior malignancies for >= 5 years with the exception of:
- •Currently treated squamous cell and basal cell carcinoma of the skin, or
- •Carcinoma in situ of the cervix, or
- •Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision , or
- •Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured, or
- •Any other malignancy that has/have been curatively treated with surgery and/or localized radiation
- •Allergic reaction/hypersensitivity to lenalidomide or history of anaphylactic shock to brentuximab vedotin in the past
- •Female only: pregnant or breastfeeding
- •Acute infection requiring systemic treatment
- •Known history of human immunodeficiency virus (HIV) infection
- •Active hepatitis B or C infection
- •Central nervous system involvement by lymphoma, including leptomeningeal involvement
- •History of progressive multifocal leukoencephalopathy (PML)
- •Current peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndrome
- •Unstable cardiac disease as defined by one of the following:
- •Cardiac events such as myocardial infarction (MI) within the past 6 months
- •NYHA (New York Heart Association) heart failure class III-IV
- •Uncontrolled atrial fibrillation or hypertension
- •History of vascular disease (e.g. deep vein thrombosis, stroke)
- •Major surgery (as defined by the investigator) within the 28 days prior to day 1 of protocol therapy
- •Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide
- •Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/psychological issues, etc.
- •Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
研究组 & 干预措施
Treatment (brentuximab vedotin, lenalidomide)
Experimental
Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Brentuximab Vedotin (Drug)
Treatment (brentuximab vedotin, lenalidomide)
Experimental
Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Lenalidomide (Drug)
Treatment (brentuximab vedotin, lenalidomide)
Experimental
Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Dose limiting toxicity (DLT) assessed per CTCAE v4.0
时间窗: Up to 21 days
次要结局
- Rate of objective global response defined as proportion of patients achieving complete response (CR)/partial response (PR) that lasts at least 4 months(At 4 months)
- Complete response defined as proportion of patients achieving CR according to Olsen criteria(Up to 1 year)
- Progression free survival (PFS) according to Olsen criteria(From start of protocol treatment to first observation of disease relapse/ progression or death from any cause, whichever occurs first, assessed up to 1 year)
- CD30 expression assessed by lymph node and/or skin biopsies via immunochemistry(Baseline)
- Change in pruritus visual analogue scale (VAS)(Up to 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralHodgkin LymphomaNCT03302728Peter MacCallum Cancer Centre, Australia6
已完成
1 期
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaLymphoma, Large B-Cell, DiffuseNCT02086604Washington University School of Medicine37
已完成
1 期
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaRecurrent Adult Hodgkin LymphomaNCT01902160National Cancer Institute (NCI)3
已完成
1 期
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent Gray-Zone LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mediastinal LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3 Follicular LymphomaRefractory Grade 3a Follicular LymphomaRefractory Gray-Zone LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Mediastinal LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaNCT02568553National Cancer Institute (NCI)35
已完成
2 期
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaLymphomatoid PapulosisPrimary Cutaneous Anaplastic Large Cell LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Cutaneous T-Cell Non-Hodgkin LymphomaStage II Cutaneous T-Cell Non-Hodgkin LymphomaStage III Cutaneous T-Cell Non-Hodgkin LymphomaStage IV Cutaneous T-Cell Non-Hodgkin LymphomaNCT03409432John Reneau26